Role of Uric Acid Metabolism-Related Inflammation in the Pathogenesis of Metabolic Syndrome Components Such as Atherosclerosis and Nonalcoholic Steatohepatitis.
Role of Uric Acid Metabolism-Related Inflammation in the Pathogenesis of Metabolic Syndrome Components Such as Atherosclerosis and Nonalcoholic Steatohepatitis.
复制标题
DOI：
10.1155/2016/8603164
复制
发表时间：
2016
影响因子：
4.6
通讯作者：
Asano T
中科院分区：
文献类型：
--
作者：
Kushiyama A;Nakatsu Y;Matsunaga Y;Yamamotoya T;Mori K;Ueda K;Inoue Y;Sakoda H;Fujishiro M;Ono H;Asano T
尿酸(UA)是嘌呤代谢的最终产物，据报道可以作为抗氧化剂。然而，最近，大量的临床和基础研究方法显示，高尿酸血症与几种疾病密切相关，特别是那些构成代谢综合征的疾病。在这篇综述中，我们首先概述了与尿酸代谢有关的炎症发生的两个分子机制：一个是尿酸结晶激活的炎症体，另一个是黄嘌呤氧化酶(XO)产生的超氧阴离子自由基。重要的是，最近的研究证明了XO抑制剂对动脉粥样硬化和非酒精性脂肪性肝炎的治疗或预防作用，这些以前被认为与高尿酸血症没有直接关系，至少没有直接关系。据报道，XO抑制剂对包括肾脏和心脏在内的其他器官也有这种有益的影响。因此，这篇综述的主要内容集中在尿酸代谢与动脉粥样硬化、非酒精性脂肪性肝炎及相关疾病的发展之间的关系。尽管有必要进行进一步的研究，但XO抑制剂是一种潜在的新策略，可以降低代谢综合征所特有的多种器官衰竭的风险。
Uric acid (UA) is the end product of purine metabolism and can reportedly act as an antioxidant. However, recently, numerous clinical and basic research approaches have revealed close associations of hyperuricemia with several disorders, particularly those comprising the metabolic syndrome. In this review, we first outline the two molecular mechanisms underlying inflammation occurrence in relation to UA metabolism; one is inflammasome activation by UA crystallization and the other involves superoxide free radicals generated by xanthine oxidase (XO). Importantly, recent studies have demonstrated the therapeutic or preventive effects of XO inhibitors against atherosclerosis and nonalcoholic steatohepatitis, which were not previously considered to be related, at least not directly, to hyperuricemia. Such beneficial effects of XO inhibitors have been reported for other organs including the kidneys and the heart. Thus, a major portion of this review focuses on the relationships between UA metabolism and the development of atherosclerosis, nonalcoholic steatohepatitis, and related disorders. Although further studies are necessary, XO inhibitors are a potentially novel strategy for reducing the risk of many forms of organ failure characteristic of the metabolic syndrome.
登录
查看更多内容
影响因子：
13.5
作者：
Csak, Timea;Ganz, Michal;Pespisa, Justin;Kodys, Karen;Dolganiuc, Angela;Szabo, Gyongyi
通讯作者：
Szabo, Gyongyi
影响因子：
3.7
作者：
Dixon LJ;Flask CA;Papouchado BG;Feldstein AE;Nagy LE
通讯作者：
Nagy LE
影响因子：
4.1
作者：
BARBER, MJ;BRAY, RC;COUGHLAN, MP
通讯作者：
COUGHLAN, MP
DOI：
10.1073/pnas.78.11.6858
发表时间：
1981-01-01
期刊：
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES
影响因子：
--
作者：
AMES, BN;CATHCART, R;HOCHSTEIN, P
通讯作者：
HOCHSTEIN, P
影响因子：
8.3
作者：
Bos, Michiel J.;Koudstaal, Peter J.;Breteler, Monique M. B.
通讯作者：
Breteler, Monique M. B.